Trial Profile

A Randomized, Open-Label, Two Part Study to Explore the Performance of Entrectinib Prototype Mini-Tablet Formulations and the Effect of Drug Substance Particle Size On Entrectinib Bioavailability in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Entrectinib (Primary) ; Entrectinib
Indications Acute myeloid leukaemia; Brain metastases; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Salivary gland cancer; Sarcoma; Solid tumours; Thyroid cancer
Focus Pharmacokinetics
Sponsors Genentech

11 Jul 2020 Planned number of patients changed from 31 to 39.
14 Aug 2019 Status changed from active, no longer recruiting to completed.
10 Jul 2019 Status changed from not yet recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com